Butyrylcholinesterase, cholinergic neurotransmission and the pathology of Alzheimer's disease

Drugs of Today

Volumn 40, Issue 8, 2004, Pages 711-721

  Geula, Changiz ^a   Darvesh, Sultan ^b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; CHOLINESTERASE;

ALZHEIMER DISEASE; CATALYSIS; CHOLINERGIC TRANSMISSION; DEGENERATIVE DISEASE; ENZYME ACTIVITY; ENZYME INHIBITION; GENETIC POLYMORPHISM; HYDROLYSIS; NEUROBIOLOGY; NEUROFIBRILLARY TANGLE; REVIEW;

ALZHEIMER DISEASE; ANIMALS; BUTYRYLCHOLINESTERASE; CHOLINESTERASE INHIBITORS; HUMANS; NEUROTRANSMITTER AGENTS;

EID: 4644320679     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2004.40.8.850473     Document Type: Review

References (91)

1. Silver, A. The Biology of Cholinesterases. Elsevier, Amsterdam 1974.
2. Tago, H., Maeda, T., McGeer, P.L., Kimura, H. Butyrylcholinesterase-rich neurons in rat brain demonstrated by a sensitive histochemical method. J Comp Neurol 1992, 325: 301-12.
3. Darvesh, S., Grantham, D.L., Hopkins, D.A. Butyrylcholinesterase in normal human amygdala and hippocampal formation. J Comp Neurol 1998, 393: 374-90.
4. Darvesh, S., MacDonald, S.E., Losier, A.M. et al. Cholinesterases in cardiac ganglia and modulation of canine intrinsic cardiac neuronal activity. J Auton Nerv Sys 1998, 71: 75-84.
5. Darvesh, S., Hopkins, D.A. Differential distribution of butyrylcholinesterase and acetylcholinesterase in the human thalamus. J Comp Neurol 2003, 463: 25-43.
6. Giacobini, E. In: Cholinesterases and Cholinesterase Inhibitors. Giacobini, E. (Ed.). Martin Dunitz Ltd., London 2000, 181-226.
7. Mesulam, M.M., Guillozet, A., Shaw, P. et al. Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine. Neuroscience 2002, 110: 627-39.
8. Atack, J.R., Perry, E.K., Bonham, J.R., Candy, J.M., Perry, R.H. Molecular forms of acetylcholinesterase and butyrylcholinesterase in the aged human central nervous system. J Neurochem 1986, 47: 263-77.
9. Geula, C., Mesulam, M.M. Special properties of Cholinesterases in the cerebral cortex of Alzheimer's disease. Brain Res 1989, 498: 185-9.
10. Arendt, T., Bruckner, M.K., Lange, M., Bigl, V. Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease resemble embryonic development-a study of molecular forms. Neurochem Int 1992, 21: 381-96.
11. Wright, C.I., Geula, C., Mesulam M.M. Neuroglial Cholinesterases in the normal brain and in Alzheimer's disease: Relationship to plaques, tangles, and patterns of selective vulnerability. Ann Neurol 1993, 34: 373-84.
12. Mesulam, M.M., Geula, C. Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia. Ann Neurol 1994, 36: 722-7.
13. Geula, C., Mesulam, M.M. Cholinesterases and the pathology of Alzheimer disease. Alzheimer Dis Assoc Disord 1995, 9: 23-8.
14. Francis, P.T., Palmer, A.M., Snape, M., Wilcock, G.K. The cholinergic hypothesis of Alzheimer's disease: A review of progress. J Neurol Neurosurg Psychiat 1999, 66: 137-47.
15. McKeith, I., Del Ser, T., Spano, P. et al. Efficacy of rivastigmine in dementia with Lewy bodies: A randomized, double-blind, placebo-controlled international study. Lancet 2000, 356: 2031-6.
16. Massoulié, J., Pezzementi, L, Bon, S., Krejci, E., Vallette, F.M. Molecular and cellular biology of cholinesterases. Prog Neurobiol 1993, 41: 31-91.
17. Taylor, P., Radić, Z. The cholinesterases: From genes to proteins. Annu Rev Pharmacol Toxicol 1994, 34: 281-320.
18. Li, B., Stribley, J.A. Jicu, A. et al. Abundant tissue butyrylcholinesterase and its possible function in the acetylcholinesterase knockout mouse. J Neurochem 2000, 75: 1320-31.
19. Mesulam, M.M., Guillozet, A., Shaw, P., Quinn, B. Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain. Neurobiol Dis 2002, 9: 88-93.
20. Lockridge, O., Mottershaw-Jackson, N., Eckerson, H., La Du, B.N. Hydrolysis of diacetylmorphine (heroin) by human serum cholinesterase. J Pharmacol Exp Ther 1980, 215: 1-8.
21. Galley, S.J. Activities of the enantiomers of cocaine and some related compounds as substrates and inhibitors of plasma butyrylcholinesterase. Biochem Pharmacol 1991, 41: 1249-54.
22. Masson, P., Froment, M.T., Fortier, P.L. et al. Butyrylcholinesterase- catalyzed hydrolysis of aspirin, a negatively charged ester, and aspirin-related neutral esters. Biochim Biophys Acta 1998, 1387: 41-52.
23. Radić, Z., Pickering, N.A., Vellom, D.C., Camp, S., Taylor P. Three distinct domains in the cholinesterase molecule confer selectivity for acetyl- and butyrylcholinesterase inhibitors. Biochemistry 1993, 32: 12074-84.
24. Saxena, A., Redman, A.M., Jiang, X., Lockridge, O., Doctor, B.P. Differences in active site gorge dimensions of cholinesterases revealed by binding of inhibitors to human butyrylcholinesterase. Biochemistry 1997, 36: 14642-51.
25. Masson, P., Froment, M.T., Bartels, C.F., Lockridge, O. Asp7O in the peripheral anionic site of human butyrylcholinesterase. Eur J Biochem 1996, 235: 36-48.
26. Vellom, D.C., Radić, Z., Li, Y. et al. Amino acid residues controlling acetylcholinesterase and butyrylcholinesterase specificity. Biochemistry 1993, 32: 12-7.
27. Lockridge, O., Bartels, C.F., Vaughan, T.A. et al. Complete amino acid sequence of human serum cholinesterase. J Biol Chem 1987, 262: 549-57.
28. Nicolet, Y., Lockridge, O., Masson, P., Fontecilla-Camps, J.C., Nachon, F. Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products. J Biol Chem 2003, 278: 41141-7.
29. Sussman, J.L., Harel, M., Frolow, F. et al. Atomic structure of acetylcholinesterase from Torpedo Californica: A prototypic acetylcholine- binding protein. Science 1991, 253: 872-9.
30. Harel, M., Sussman, J.L., Krejci, E. et al. Conversion of acetylcholinesterase to butyrylcholinesterase: Modeling and mutagenesis. Proc Natl Acad Sci USA 1992, 89: 10827-31.
31. Soreq, H., Seidman, S. Acetylcholinesterase - New roles for an old actor. Nature Rev Neurosci 2001, 2: 294-302.
32. George, ST., Balasubramanian, A.S. The aryl acylamidases and their relationship to cholinesterases in human serum, erythrocyte and liver. Eur J Biochem 1981, 121: 177-86.
33. Majumdar, R., George, ST., Balasubramanian, A.S. Serotonin-sensitive aryl acylamidase activity of platelet acetylcholinesterase. Biochem Pharmacol 1982, 31: 2319-25.
34. Darvesh, S., Kumar, R., Roberts, S., Walsh, R., Martin, E. Butyrylcholinesterase-mediated enhancement of the enzymatic activity of trypsin. Cell Mol Neurobiol 2001, 21: 285-9.
35. Katona, G., Berglund, G.I., Hajdu, J., Graf, L, Szilagyi, L. Crystal structure reveals basis for the inhibitor resistance of human brain trypsin. J Mol Biol 2002, 315: 1209-18.
36. Massoulie, J., Bon, S. The molecular forms of cholinesterase and acetylcholinesterase in vertebrates. Annu Rev Neurosci 1982, 5: 57-106.
37. Massoulie, J. The origin of the molecular diversity and functional anchoring of cholinesterases. Neurosignals 2002, 11: 130-43.
38. Perrier, A.L., Massoulie, J., Krejci, E. PRIMA: the membrane anchor of acetylcholinesterase in the brain. Neuron 2002, 33: 275-85.
39. Prody, C.A., Zevin-Sonkin, D., Gnatt, A., Goldberg, O., Soreq, H. Isolation and characterization of full-length cDNA clones coding for cholinesterase from fetal human tissues. Proc Natl Acad Sci USA 1987, 84: 3555-9.
40. Allderdice, P.W., Gardner, H.A., Galutira, D. et al. The cloned butyrylcholinesterase (BCHE) gene maps to a single chromosome site, 3q26. Genomics 1991, 11: 452-4.
41. Gaughan, G., Park, H., Priddle, J., Craig, I., Craig, S. Refinement of the localization of human butyrylcholinesterase to chromosome 3q26.1-q26.2 using a PCR-derived probe. Genomics 1991, 11: 455-8.
42. Arpagaus, M., Kott, M., Vatsis, K.P. et al. Structure of the gene for human butyrylcholinesterase. Evidence for a single copy. Biochemistry 1990, 9: 124-31.
43. Getman, D.K., Eubanks, J.H., Camp, S., Evans, G.A., Taylor, P. The human gene encoding acetylcholinesterase is located on the long arm of chromosome 7. Am J Hum Genet 1992, 51: 170-7.
44. Roychoudhury, A.K., Nei, M. Human Polymorphic Genes: World Distribution. Oxford University Press, New York 1988.
45. La Du, B.N., Bartels, C.F., Nogueira, C.P. et al. Phenotypic and molecular biological analysis of human butyrylcholinesterase variants. Clin Biochem 1990, 23: 423-31.
46. La Du, B.N., Bartels, C.F., Nogueira, C.P., Arpagaus, M., Lockridge, O. Proposed nomenclature for human butyrylcholinesterase genetic variants identified by DNA sequencing. Cell Mol Neurobiol 1991, 11: 79-89.
47. McGuire, M.C., Nogueira, C.P., Bartels, C.V. et al. Identification of the structural mutation responsible for the dibucaine-resistant (atypical) variant form of human serum cholinesterase. Proc Natl Acad Sci USA 1989, 86: 953-7.
48. Neville, L.F., Gnatt, A., Padan, R., Seidman, S., Soreq, H. Anionic site interactions in human butyrylcholinesterase disrupted by two single point mutations. J Biol Chem 1990, 265: 20735-8.
49. Bartels, C.F., Jensen, F.S., Lockridge, O. et al. DNA mutation associated with the human butyrylcholinesterase K-variant and its linkage to the atypical variant mutation and other polymorphic sites. Am J Hum Genet 1992, 50: 1086-103.
50. Bartels, C.F., James, K., La Du, B.N. DNA mutations associated with the human butyrylcholinesterase J-variant. Am J Hum Genet 1992, 50: 1104-14.
51. Rubinstein, H.M., Dietz, A.A., Lubrano, T. E1k, another quantitative variant at cholinesterase locus 1. J Med Genet 1978, 15: 27-9.
52. Garry, P.J., Dietz, A.A., Lubrano, T. et al. New allele at cholinesterase locus 1. J Med Genet 1976, 13: 38-42.
53. Primo-Parmo, S.L., Bartels, C.F., Wiersema, B. et al. Characterization of 12 silent alleles of the human butyrylcholinesterase (BCHE) gene. Am J Hum Genet 1996, 58: 52-64.
54. Liddell, J., Lehmann, H., Silk, E. A "silent" pseudocholinesterase gene. Nature 1962, 193: 561-2.
55. Friede, R.L. Enzyme histochemical studies of senile plaques. J Neuropathol Exp Neurol 1965, 24: 477-91.
56. Mesulam, M.M., Geula, C., Brimijoin, S., Smiley, J.F. Butyrylcholinesterase immunochemistry in human cerebral cortex. Soc Neurosci Abst 1995, 21: 1976.
57. Greig, N.H., Utsuki, T., Yu, Q. et al. A new therapeutic target in Alzheimer's disease: Attention to butyrylcholinesterase. Curr Med Res Opin 2001, 17: 159-65.
58. Geula, C. In: Early Diagnosis of Alzheimer's Disease. Scinto, L.F.M., Daffner, K.R. (Eds.). Humana Press, Totowa, New Jersey 2000, 65-82.
59. Hardy, J., Selkoe, D.J. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 2002, 297: 353-6.
60. Selkoe, D.J. Aging, amyloid and Alzheimer's disease. Neurochem Res 2003, 28: 1705-13.
61. Selkoe, DJ., Schenk, D. Alzheimer's disease: Molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol 2003, 43: 545-84.
62. Perry, E.K., Perry, R.H., Blessed, G., Tomlinson, B.E. Necropsy evidence of central cholinergic deficits in senile dementia. Lancet 1977, 1: 189.
63. Geula, C., Mesulam, M.M. In: Alzheimer Disease, 2nd ed. Terry, R., Katzman, R., Bick, K., Sisodia, S.S. (Eds.). Lippincott Williams and Wilkins, Philadelphia 1999, 269-92.
64. Perry, E.K., Perry, R.H., Blessed, G., Tomlinson, E. Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropath Appl Neurobiol 1978, 4: 273-7.
65. Guillozet, A.L., Smiley, J.F., Mash, D.C., Mesulam, M.M. Butyrylcholinesterase in the life cycle of amyloid plaques. Ann Neurol 1997, 42: 909-18.
66. Eskander, M., Nagykery, N., Leung, E., Scinto, L.F., Geula, C. Inhibition of plaque and tangle associated cholinesterases by rivastigmine. Soc Neurosci Abstr. (Nov. 8-12, New Orleans) 2003, 29: Session # 240.9.
67. Wright, C.I., Geula, C., Mesulam, M.M. Protease inhibitors and indoleamines selectively inhibit cholinesterases in the histopathologic structures of Alzheimer's disease. Proc Natl Acad Sci USA 1993, 90: 683-6.
68. Lehmann, D.J., Johnston, C., Smith, A.D. Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset confirmed Alzheimer's disease. Hum Molec Genet 1997, 6: 1933-6.
69. Lehmann, D.J., Nagy, Z., Litchfield, S., Borja, M.C., Smith, A.D. Association of butyrylcholinesterase K variant with cholinesterase-positive neuritic plaques in the temporal cortex in late-onset Alzheimer's disease. Hum Genet 2000, 106: 447-52.
70. McIlroy, S.P., Crawford, V.L., Dynan, K.B. et al. Butyrylcholinesterase K variant is genetically associated with late onset Alzheimer's disease in Northern Ireland. J Med Gen 2000, 37: 182-5.
71. Tilley, L., Morgan, K., Grainger, J. et al. Evaluation of polymorphisms in the presenilin-1 gene and the butyrylcholinesterase gene as risk factors in sporadic Alzheimer's disease. Eur J Hum Gen 1999, 7: 659-63.
72. Wiebusch, H., Poirier, J., Sevigny, P., Schappert, K. Further evidence for a synergistic association between APOE epsilon4 and BCHE-K in confirmed Alzheimer's disease. Hum Gen 1999, 104: 158-63.
73. Alvarez-Arcaya, A., Combarros, O., Llorca, J. et al. The butyrylcholinesterase K variant is a protective factor for sporadic Alzheimer's disease in women. Acta Neurol Scand 2000, 102: 350-3.
74. Ki, C.S., Na, D.L., Kim, J.W. et al. No association between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset Alzheimer's disease. Am J Med Gen 1999, 88: 113-35.
75. Singleton, A.B., Smith, G., Gibson, A.M. et al. No association between the K variant of the butyrylcholinesterase gene and pathologically confirmed Alzheimer's disease. Hum Mol Gen 1998, 7: 937-9.
76. Ballard, G.G., Jacoby, R., Del Ser, T. et al. Regulation of attention and rate of progression of cognitive deficits by butyrylcholinesterase in DLB and moderate/severe Alzheimer's disease. Neurology 2002, 58: A42.
77. Mattila, K.M., Rinne, J.O., Roytta, M. et al. Dipeptidyl carboxypeptidase 1 (DCP1) and Butyrylcholinesterase (BCHE) gene interactions with the apolipoprotein E epsilon4 allele as risk factors in Alzheimer's disease and in Parkinson's disease with coexisting Alzheimer pathology. J Med Gen 2000, 37: 766-70.
78. Barber, K.L., Mesulam, M.M., Krafft, G.A., Klein, W.L. Butyrylcholinesterase alters the aggregation state of Aβ amyloid. Soc Neurosci Abstr. 1996, 72: 1172.
79. Lahiri, O.K., Farlow, M.R., Hintz, N., Utsuki, T., Greig, N.H. Cholinesterase inhibitors, beta-amyloid precursor protein and amyloid beta-peptides in Alzheimer's disease. Acta Neurol Scand (Suppl) 2000, 176: 60-7.
80. Shaw, K.T., Utsuki, T., Rogers, J. et al. Phenserine regulates translation of beta-amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development. Proc Natl Acad Sci USA 2001, 98: 7605-10.
81. Sim, A., Walsh, R., Humar, R. Rivastigmine: A review. Hosp Med 1999, 60: 731-5.
82. McKenna, M.T., Proctor, G.R., Young, L.C., Harvey, A.L. Novel tacrine analogues for potential use against Alzheimer's disease: Potent and selective acetylcholinesterase inhibitors and 5-HT uptake inhibitors. J Med Chem 1997, 40: 3516-23.
83. Darvesh, S., Walsh, R., Humar, R. et al. Inhibition of human cholinsterases by drugs used to treat Alzheimer disease. Alzheimer Dis Assoc Disor 2003, 17: 117-26.
84. Qizilbash, N., Whitehead, A., Higgins, J. et al. Cholinesterase inhibition for Alzheimer disease: A meta-analysis of the tacrine trials. Dementia Trialists' Collaboration. JAMA 1998, 280: 1777-82.
85. Giacobini, E., Spiegel, R., Enz, A., Veroff, A.E., Cutler, N.R. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: Correlation with cognitive benefit. J Neural Transm 2002, 109: 1053-65.
86. Farlow, M., Anand, R., Messina, J. Jr., Hartman, R., Veach, J. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol 2000, 44: 236-41.
87. Corey-Bloom, J., Tiraboschi, P., Hansen, L.A. et al. A randomised trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderate severe Alzheimer's disease. Int J Geriatr Psychiat 1998, 1: 55-65.
88. Mesulam, M.M., Geula, C., Moran, A. Anatomy of cholinesterase inhibition in Alzheimer's disease: Effect of physostigmine and tetrahydroaminoacridine on plaques and tangles. Ann Neurol 1987, 22: 683-91.
89. Farlow, M., Potkin, S., Khoumaras, B., Veach, J., Mirski, D. Analysis of outcome in retrieved dropout patients in a rivastigmine vs. placebo, 26-week, Alzheimer disease trial. Arch Neurol 2003, 60: 843-8.
90. Kuljis, P.O., Farlow, M., Grossberg, G. et al. Long-term exposure to rivastigmine may reduce senile plaque density. Soc Neurosci Abstr. (Nov. 8-12, New Orleans) 2003, 29: Session #240.10.
91. Darreh-Shori, T., Almkvist, O., Guan, Z.Z. et al. Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months. Neurology 2002, 59: 563-72.